Abstract
Forty-three patients with chronic myeloid leukaemia have been treated with hydroxyurea in order to be subjected to leucopheresis for white cell transfusions. Hydroxyurea decreases leucocytosis when it is administered and the blood granulocyte number increases soon after the drug is stopped. The survival of the patients is not different from the survival of the patients treated with conventional chemotherapy (busulphan, mitobronitol) and it is superior to the survival of patients treated with external radiotherapy or with 32P. Half of the patients were subjected to splenectomy during first remission for a phase II trial. They were not randomized, but the distribution according to age was similar in the two groups. A slight difference appears in favour of splenectomy so far as survival is concerned, but there were three post-operative deaths out of 18 patients. We conclude that a phase II trial on the value of splenectomy is indicated ethically, but that the patients should be operated on and nursed in a microbiologically controlled environment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cattan A., Schneider M., Schwarzenberg L., Amiel J. J., Schlumberger J. R., Gluckman E., Mathé G. Essai de traitement de la leucémie myéloïde chronique par 3 nouveaux composés chimiothérapiques: le dibromomannitol, l'hydroxyurée et la désacétamidocolchicine. Sem Hop. 1966 Nov 26;42(49):2966–2969. [PubMed] [Google Scholar]
- FISHBEIN W. N., CARBONE P. P., FREIREICH E. J., MISRA D., FREI E., 3rd CLINICAL TRIALS OF HYDROXYUREA IN PATIENTS WITH CANCER AND LEUKEMIA. Clin Pharmacol Ther. 1964 Sep-Oct;5:574–580. doi: 10.1002/cpt196455574. [DOI] [PubMed] [Google Scholar]
- FREIREICH E. J., LEVIN R. H., WHANG J., CARBONE P. P., BRONSON W., MORSE E. E. THE FUNCTION AND FATE OF TRANSFUSED LEUKOCYTES FROM DONORS WITH CHRONIC MYELOCYTIC LEUKEMIA IN LEUKOPENIC RECIPIENTS. Ann N Y Acad Sci. 1964 Feb 28;113:1081–1089. doi: 10.1111/j.1749-6632.1964.tb40726.x. [DOI] [PubMed] [Google Scholar]
- GALTON D. A., TILL M. Myleran in chronic myeloid leukaemia. Lancet. 1955 Feb 26;268(6861):425–430. doi: 10.1016/s0140-6736(55)90212-9. [DOI] [PubMed] [Google Scholar]
- MATHE G., SCHNEIDER M., CATTAN A., SCHWARZENBERG L., AMIEL J. L. ESSAI DE TRAITEMENT DE LA LEUC'EMIE MY'ELOIDE CHRONIQUE PAR LE DIBROMOMANNITOL. Presse Med. 1964 Sep 12;72:2135–2136. [PubMed] [Google Scholar]
- REINHARD E. H., NEELY C. L., SAMPLES D. M. Radioactive phosphorus in the treatment of chronic leukemias: long-term results over a period of 15 years. Ann Intern Med. 1959 Apr;50(4):942–958. doi: 10.7326/0003-4819-50-4-942. [DOI] [PubMed] [Google Scholar]
- SELLEI C., ECKHARDT S. [Trial treatment of neoplastic diseases by 1,6-dibromomannitol]. Rev Fr Etud Clin Biol. 1963 May;8:483–484. [PubMed] [Google Scholar]
- Schwarzenberg L., Mathé G., de Grouchy J., de Nava C., de Vries M. J., Amiel J. L., Cattan A., Schneider M., Schlumberger J. R. White blood cell transfusions. Isr J Med Sci. 1965 Sep;1(5):925–956. [PubMed] [Google Scholar]